Previously, umbilical cord blood stem cells were good for children but now this is safe and effective for adults with blood cancers.
They grew more umbilical cord blood stem cells outside the body then transplanted it into an adult blood cancer patients. They were able to restore a normal of blood cells.
Immune therapy company Gamida Cell produces this umbilical cord blood stem cell treatment known as NiCord, and after more successful trials plan to seek approval from the FDA.
Widecells Group PLC (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.